Cargando…

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

BACKGROUND: Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes. METHODS: Thirty-f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sezai, Akira, Sekino, Hisakuni, Unosawa, Satoshi, Taoka, Makoto, Osaka, Shunji, Tanaka, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551875/ https://www.ncbi.nlm.nih.gov/pubmed/31167663 http://dx.doi.org/10.1186/s12933-019-0877-2

Ejemplares similares

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)
por: Sezai, Akira, et al.
Publicado: (2019)

A Comparative Study to Investigate the Effects of Bisoprolol in Patients with Chronic Heart Failure and Hypertension When Switched from Tablets to Transdermal Patches
por: Sezai, Akira, et al.
Publicado: (2023)

A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia
por: Sezai, Akira, et al.
Publicado: (2023)

Iatrogenic acute aortic dissection caused by intervention for spontaneous coronary artery dissection: a surgical case report
por: Hayashi, Yuki, et al.
Publicado: (2020)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
por: Sezai, Akira, et al.
Publicado: (2022)

A Comparative Prospective Observational Study on the Use of Direct Oral Anticoagulants after Cardiac Surgery for the Management of Atrial Fibrillation
por: Sezai, Akira, et al.
Publicado: (2020)

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Does Epicardial Adipose Tissue Influence Postoperative Atrial Fibrillation?
por: Kogo, Hiroko, et al.
Publicado: (2018)

Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
por: Kusunose, Kenya, et al.
Publicado: (2021)

Appropriate Needle Length Determined by Ultrasonic Echography for Intramuscular Injection in Japanese Elderly over 50 Years
por: Nakayama, Tetsuo, et al.
Publicado: (2022)

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Efficacy of Early Cardiac Rehabilitation After Cardiac Surgery　― Verification Using Japanese Diagnosis Procedure Combination Data ―
por: Sezai, Akira, et al.
Publicado: (2022)

Mode of death in elderly and super‐elderly patients with acute heart failure: Insights from Japanese heart failure registry
por: Takabayashi, Kensuke, et al.
Publicado: (2021)

Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
por: Nasiri-Ansari, Νarjes, et al.
Publicado: (2018)

Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
por: Martín, Ernesto, et al.
Publicado: (2022)

Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction
por: Ma, Sai, et al.
Publicado: (2022)

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Acquisition of Humoral Immune Responses in Convalescent Japanese People with SARS-CoV-2 (COVID-19) Infection in 2021
por: Monzen, Koshiro, et al.
Publicado: (2023)

Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects
por: Shiba, Sari, et al.
Publicado: (2020)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018)

Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D(2)/D(3) Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants
por: Yamaguchi, Takayoshi, et al.
Publicado: (2021)

Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Kitai, Takeshi, et al.
Publicado: (2020)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Sinclair, Alan J., et al.
Publicado: (2016)

Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
por: Nandula, Seshagiri Rao, et al.
Publicado: (2021)

Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2021)

Long Term Follow-Up Study of a Randomized, Open-Label, Uncontrolled, Phase I/II Study to Assess the Safety and Immunogenicity of Intramuscular and Intradermal Doses of COVID-19 DNA Vaccine (AG0302-COVID19)
por: Nakagami, Hironori, et al.
Publicado: (2023)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
por: Spertus, John A., et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Depressive symptoms in asymptomatic stage B heart failure with Type II diabetic mellitus
por: Mills, Paul J., et al.
Publicado: (2019)

Thymopentin improves cardiac function in older patients with chronic heart failure
por: Xiaojing, Cao, et al.
Publicado: (2017)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
por: Soga, Fumitaka, et al.
Publicado: (2018)

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

The Relationship between Preheparin Lipoprotein Lipase and Metabolic Derangements in Obese Japanese Children
por: Abe, Yuki, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_q90fflkbucdbrtg3s2gvo5b319